生命科学资讯

Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer

Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse

Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook

'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments

FDA rejects Disc's rare disease drug despite commissioner's voucher

With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment

FDA clears Encora Therapeutics’ wearable wrist device for essential tremor

What were the biggest clinical trial flops of 2025?

After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio

Chutes & Ladders—Sanofi's stunning CEO switch

Integra LifeSciences cuts roles as 65 staffers impacted from Princeton, N.J., site

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg

Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans

'When the markets opened, we were ready': Why biotech IPOs are back for 2026

Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance

Lundbeck’s migraine prevention treatment sees ph. 2 success after trial’s earlier setback

BridgeBio preps approval push after dwarfism drug increases children's height in phase 3